Spotlight Therapeutics Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
32
- Latest Deal Type
-
M&A
Spotlight Therapeutics General Information
Description
Operator of a biotechnology platform intended to develop a new class of therapeutics by direct cell-targeted in vivo gene editing. The company's platform delivers CRISPR nuclease effectors to selected cell types in vivo, with initial programs in immuno-oncology, ophthalmology, and hematology, and is building a pipeline of immuno-oncology programs addressing pre-clinically validated, but classically undruggable, intracellular gene targets in addition to differentiated CRISPR-validated monogenic disease targets of the eye, enabling healthcare providers to address the limitations of the cell, viral, and nanoparticle-mediated delivery for gene editing. .
Contact Information
Website
www.spotlighttx.comCorporate Office
- 3980 Trust Way
- Hayward, CA 94545
- United States
Corporate Office
- 3980 Trust Way
- Hayward, CA 94545
- United States
Spotlight Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | Completed | Pre-Clinical Trials | ||||
| 5. Later Stage VC (Series B) | 04-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A2) | 30-Nov-2020 | Completed | Startup | |||
| 3. Early Stage VC (Series A1) | 25-Sep-2019 | Completed | Startup | |||
| 2. Seed Round | 02-Jan-2018 | $7.27M | $7.27M | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2017 | Completed | Startup |
Spotlight Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A2 | ||||||||
| Series A1 | 6,388,886 | $0.000100 | $0.09 | $1.08 | $1.08 | 1x | $1.08 | 13.17% |
| Series A | 8,133,334 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 16.77% |
Spotlight Therapeutics Comparisons
Industry
Financing
Details
Spotlight Therapeutics Competitors (96)
One of Spotlight Therapeutics’s 96 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Amber (Biotechnology) | Venture Capital-Backed | San Francisco, CA | ||||
| MeiraGTx | Formerly VC-backed | New York, NY | ||||
| ERS Genomics | Corporate Backed or Acquired | Dublin, Ireland |
Spotlight Therapeutics Patents
Spotlight Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025038950-A1 | Cell-penetrating peptide compositions and uses thereof | Inactive | 16-Aug-2023 | ||
| WO-2024226822-A2 | Cd11a tage compositions and uses thereof | Inactive | 26-Apr-2023 | ||
| WO-2024226822-A3 | Cd11a tage compositions and uses thereof | Inactive | 26-Apr-2023 | ||
| WO-2024077184-A2 | Cd11a tage compositions and uses thereof | Inactive | 05-Oct-2022 | ||
| WO-2024077184-A3 | Cd11a tage compositions and uses thereof | Inactive | 05-Oct-2022 | C07K16/2818 |
Spotlight Therapeutics Signals
Spotlight Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DNA Capital (Investor) | Venture Capital | Minority | ||
| EPIQ Capital Group | Family Office | Minority | ||
| Emerson Collective | Impact Investing | Minority | ||
| Foothill Ventures | Venture Capital | Minority | ||
| GV | Corporate Venture Capital | Minority |
Spotlight Therapeutics FAQs
-
When was Spotlight Therapeutics founded?
Spotlight Therapeutics was founded in 2017.
-
Where is Spotlight Therapeutics headquartered?
Spotlight Therapeutics is headquartered in Hayward, CA.
-
What is the size of Spotlight Therapeutics?
Spotlight Therapeutics has 32 total employees.
-
What industry is Spotlight Therapeutics in?
Spotlight Therapeutics’s primary industry is Biotechnology.
-
Is Spotlight Therapeutics a private or public company?
Spotlight Therapeutics is a Private company.
-
What is Spotlight Therapeutics’s current revenue?
The current revenue for Spotlight Therapeutics is .
-
How much funding has Spotlight Therapeutics raised over time?
Spotlight Therapeutics has raised $66.5M.
-
Who are Spotlight Therapeutics’s investors?
DNA Capital (Investor), EPIQ Capital Group, Emerson Collective, Foothill Ventures, and GV are 5 of 9 investors who have invested in Spotlight Therapeutics.
-
Who are Spotlight Therapeutics’s competitors?
Regenxbio, Genetix Biotherapeutics, Amber (Biotechnology), MeiraGTx, and ERS Genomics are some of the 96 competitors of Spotlight Therapeutics.
-
Who acquired Spotlight Therapeutics?
Spotlight Therapeutics was acquired by Stipple Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process